Biopharma Quarterly Dealmaking Statistics, Q4 2016
A look at financing, M&A and alliance activity October–December 2016
Executive Summary
Biopharma companies closed out 2016 with $9.6 billion in financing, the strongest quarter of the year. M&A deals reached $12.2 billion in value, led by Lonza's takeover of Capsugel; most of the fourth quarter's largest partnerships were built around innovative platforms in antibodies, peptides and gene therapy.
You may also be interested in...
Early Stage Biopharma Financings Kept Up Multibillion-Dollar Pace In 2016
Series A venture capital and seed funding rounds for biopharma firms in 2016 kept pace with the level of investment seen in 2015, excluding one major deal in 2015, laying the foundation for optimism regarding early-stage financings in 2017 for particularly innovative companies.
New Parent Lonza Welcomes Capsugel's Independent Streak To Innovate
Lonza acquires Capsugel for $5.5bn cash, nearly twice as much as private equity firm KKR paid Pfizer for it, to enhance its product development and expand the market for its contract development and manufacturing services for drug and nutritional products.
Prestige Brands Acquires C.B. Fleet, Boosts Women’s OTC Platform
Prestige Brands makes the deal three weeks after divesting the slower-selling Massengill douche brand and as it makes a top marketing priority of growing sales of its Monistat yeast treatment line.